(0.16%) 5 316.45 points
(0.22%) 39 997 points
(0.11%) 16 761 points
(0.70%) $79.18
(3.15%) $2.49
(-0.40%) $2 385.40
(0.64%) $29.92
(-0.14%) $1 068.60
(0.11%) $0.920
(0.27%) $10.69
(0.04%) $0.789
(0.16%) $90.83
Quarter results today
(bmo 2024-05-16)
Expected move: +/- 6.52%
@ $17.99
Issued: 14 Feb 2024 @ 15:07
Return: 38.69%
Previous signal: Feb 14 - 14:44
Previous signal:
Return: 1.47 %
Live Chart Being Loaded With Signals
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States...
Stats | |
---|---|
Today's Volume | 364 990 |
Average Volume | 743 390 |
Market Cap | 1.07B |
EPS | $0 ( 2024-05-09 ) |
Next earnings date | ( $-0.980 ) 2024-06-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.76 |
ATR14 | $0.0890 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-06 | Michaelson Jennifer | Buy | 50 000 | Common Stock |
2024-05-06 | Michaelson Jennifer | Sell | 37 723 | Common Stock |
2024-05-06 | Michaelson Jennifer | Sell | 50 000 | Stock Option (Right to Buy) |
2024-05-07 | Michaelson Jennifer | Buy | 5 606 | Common Stock |
2024-05-07 | Michaelson Jennifer | Sell | 5 606 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
54.92 |
Last 99 transactions |
Buy: 2 506 121 | Sell: 594 695 |
Volume Correlation
Cullinan Oncology, LLC Correlation
10 Most Positive Correlations | |
---|---|
BNIXU | 0.96 |
SGEN | 0.914 |
NTIC | 0.895 |
ATVI | 0.879 |
CSLM | 0.876 |
STAY | 0.876 |
VLATU | 0.874 |
TIOAU | 0.872 |
FTIV | 0.871 |
RADI | 0.87 |
10 Most Negative Correlations | |
---|---|
RMRM | -0.924 |
NMTR | -0.915 |
PCH | -0.897 |
CETX | -0.891 |
TLGT | -0.887 |
AUGX | -0.878 |
GLBS | -0.875 |
CZR | -0.874 |
IDBA | -0.871 |
VOXX | -0.87 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cullinan Oncology, LLC Correlation - Currency/Commodity
Cullinan Oncology, LLC Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-310 000 (0.00 %) |
EPS: | $-3.69 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-310 000 (0.00 %) |
EPS: | $-3.69 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-93 000.00 (0.00 %) |
EPS: | $2.46 |
FY | 2021 |
Revenue: | $18 943.00 |
Gross Profit: | $18 943.00 (100.00 %) |
EPS: | $-0.00157 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cullinan Oncology, LLC
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators